AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:38 2024-07-17 pm EDT			5-day change	1st Jan Change
175.3 ^USD	+3.59%		+4.24%	+13.10%

Jul. 17	TD Cowen Adjusts Price Target on AbbVie to $195 From $180	MT
Jul. 12	AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis	MT

AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call

January 09, 2023 at 04:46 am EST

AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens.

AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

AbbVie logo

SOURCE AbbVie

Contact(s)

Media

Frank Benenati

(224) 688-4169

Frank.Benenati@abbvie.com or

Investors

Liz Shea

(847) 935-2211

Liz.Shea@abbvie.com

Latest news about AbbVie Inc.

TD Cowen Adjusts Price Target on AbbVie to $195 From $180	Jul. 17	MT
AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis	Jul. 12	MT
AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis	Jul. 12	DJ
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191	Jul. 11	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207	Jul. 10	MT
Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer	Jul. 10	CI
Mixed feelings	Jul. 09
That's not so bad, is it?	Jul. 08
Sector Update: Health Care Stocks Steady Premarket Friday	Jul. 05	MT
AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Jul. 05	MT
AbbVie cuts 2024 profit forecast	Jul. 03	RE
Merus Names New Chief Medical Officer	Jul. 01	MT
AbbVie: new CEO takes up post	Jul. 01	CF
AbbVie Says Robert Michael Assumes CEO Role	Jul. 01	MT
AbbVie Announces Board Changes	Jul. 01	CI
AbbVie Inc.(NYSE:ABBV) added to Russell Top 200 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value-Defensive Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000E Value Index	Jun. 30	CI
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	Jun. 27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Jun. 27	MT

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

175.3 USD

Average target price

183.8 USD

Spread / Average Target

+4.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+13.10%	310B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.36%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ASTRAZENECA PLC	+16.49%	247B
NOVARTIS AG	+14.94%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B
SANOFI	+3.00%	126B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call

EPS Revisions